Brcaone 150mg Tablet

Breast cancer and ovarian cancer

Brcaone 150mg tablet also show various side effects which are acute or chronic as well. Some patients may resolve on their own but some need proper medical attention to cure the disease. Visit the doctor if these symptoms may persist or worsen at the time of treatment:
● Muscle cramps
● Confusion, visual disturbances, seizures, and headache
● Breathlessness
● Swelling of feet
● Changes in heartbeat
● High blood pressure
● Pneumonia
● Loss of appetite
● Sensitivity, tingling and burning sensation of the skin
● Nausea, vomiting, and diarrhea
● Mouth ulcers
● Constipation

The correct dosage and duration of Brcaone 150mg tablet is recommended by the healthcare professional. Doctors prescribed this medication with or without food based on patient response to the treatment. Do not self administered, follow the recommended dosage as prescribed by the doctor to ensure safe and effective treatment option.

Brcaone 150mg tablet is a targeted therapy which contains PARP (inhibitor that works by the blocking PARP enzyme to stop cancer cell from repairing their DNA, leading to cell death. The medication slowly stops the progression of the disease and helps prevent the spread or further growth of cancer in the body.

• Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018). Olaparib for the treatment of breast cancer. Expert review of anticancer therapy, 18(6), 519-530.
• Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., ... & Domchek, S. M. (2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. Journal of clinical oncology, 33(3), 244-250.
• Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., ... & Domchek, S. M. (2015). Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. Journal of clinical oncology, 33(3), 244-250.
• Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., ... & Carmichael, J. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet, 376(9737), 235-244.
• Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., ... & Saad, F. (2022). Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM evidence, 1(9), EVIDoa2200043.